Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 26Genitourinary 16Plasma cell 10Thoracic 5Sarcoma 4Gastrointestinal 4Head & Neck 3Tumor-Agnostic 2Other solid neoplasm 2Lymphoid 2Gynecologic 2Endocrine 2Dermatologic 2Other hematologic neoplasm 1Myeloid 1

Conditions

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Ovarian Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Denosumab × Gynecologic × Clear all
NCT06513624 2025-07-25

ETC-159-02

National University Hospital, Singapore

Phase 1 Recruiting
16 enrolled
Gynecologic

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT03382574 2022-06-14

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Terminated
2 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡